These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22846375)

  • 1. Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer.
    Ding X; Dai H; Hui Z; Ji W; Liang J; Lv J; Zhou Z; Yin W; He J; Wang L
    Radiat Oncol; 2012 Jul; 7():119. PubMed ID: 22846375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for brain metastases in completely resected small cell lung cancer: a retrospective study to identify patients most likely to benefit from prophylactic cranial irradiation.
    Zhu H; Bi Y; Han A; Luo J; Li M; Shi F; Kong L; Yu J
    Radiat Oncol; 2014 Sep; 9():216. PubMed ID: 25239373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer.
    Nakagiri T; Sawabata N; Funaki S; Inoue M; Kadota Y; Shintani Y; Okumura M
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):733-8. PubMed ID: 21297135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma.
    Tian C; Liu G; Xu Y; Xia G; Zhang T; Huang J; Jiang H; Ming Wang J; Li B
    Radiol Oncol; 2020 Dec; 55(1):66-76. PubMed ID: 33885242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation.
    Ji Z; Bi N; Wang J; Hui Z; Xiao Z; Feng Q; Zhou Z; Chen D; Lv J; Liang J; Fan C; Liu L; Wang L
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):330-7. PubMed ID: 24725335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
    Sun A; Hu C; Wong SJ; Gore E; Videtic G; Dutta S; Suntharalingam M; Chen Y; Gaspar LE; Choy H
    JAMA Oncol; 2019 Jun; 5(6):847-855. PubMed ID: 30869743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy.
    Li N; Zeng ZF; Wang SY; Ou W; Ye X; Li J; He XH; Zhang BB; Yang H; Sun HB; Fang Q; Wang BX
    Ann Oncol; 2015 Mar; 26(3):504-9. PubMed ID: 25515658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of subgroup patients with stage IIIB/IV non-small cell lung cancer at higher risk for brain metastases.
    Hsiao SH; Chung CL; Chou YT; Lee HL; Lin SE; Liu HE
    Lung Cancer; 2013 Nov; 82(2):319-23. PubMed ID: 24018025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of brain metastases as initial failure in completely resected stage IIIA(N2) non-small cell lung cancer.
    Zhang Q; Cai XW; Feng W; Yu W; Fu XL
    Ann Transl Med; 2020 Mar; 8(6):374. PubMed ID: 32355818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Cranial Irradiation Reduces Brain Metastases and Improves Overall Survival in High-Risk Metastatic Non-Small Cell Lung Cancer Patients: A Randomized phase 2 Study (PRoT-BM trial).
    Arrieta O; Maldonado F; Turcott JG; Zatarain-Barrón ZL; Barrón F; Blake-Cerda M; Cabrera-Miranda LA; Cardona AF; de la Garza JG; Rosell R
    Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1442-1450. PubMed ID: 33640422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival benefit of skip metastases in surgically resected N2 non-small cell lung cancer: A multicenter observational study of a large cohort of the Chinese patients.
    Li X; Li X; Fu X; Liu L; Liu Y; Zhao H; Li Y; Hu J; Xu L; Liu D; Yang H; Zhang X
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1874-1881. PubMed ID: 31902592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resected non-small cell bronchogenic carcinoma stage pIIIA-N2. Which patients will benefit most from adjuvant therapy?].
    Gómez AM; Jarabo JR; Fernandez C; Calatayud J; Fernández E; Torres AJ; Balibrea JL; Hernando F;
    Cir Esp; 2014 Apr; 92(4):277-82. PubMed ID: 23453425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients.
    Wang CL; Li Y; Yue DS; Zhang LM; Zhang ZF; Sun BS
    World J Surg; 2012 Feb; 36(2):455-62. PubMed ID: 22187129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer.
    Sun DS; Hu LK; Cai Y; Li XM; Ye L; Hou HY; Wang CH; Jiang YH
    Asian Pac J Cancer Prev; 2014; 15(3):1233-9. PubMed ID: 24606446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and outcome of surgically treated patients with brain metastases of non-small cell lung cancer.
    She C; Wang R; Lu C; Sun Z; Li P; Yin Q; Liu Q; Wang P; Li W
    Thorac Cancer; 2019 Feb; 10(2):137-142. PubMed ID: 30485664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
    Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.
    Tamura M; Matsumoto I; Saito D; Yoshida S; Takata M; Takemura H
    World J Surg Oncol; 2016 Nov; 14(1):295. PubMed ID: 27884195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.